Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1996, for Cheung Laboratories, Inc. (Note: The input metadata listed "Imunon, Inc.", but the filing text explicitly identifies the registrant as Cheung Laboratories, Inc., a Maryland corporation). The Company is a medical device manufacturer specializing in microwave hyperthermia systems for cancer and benign prostatic hyperplasia (BPH) treatment. During this period, management announced a strategic pivot to exit its industrial division (cosmetics/fine chemicals) to refocus resources on its core medical technology business.
Key Financial Metrics
| Metric | Q2 1996 | Q2 1995 |
|---|---|---|
| Total Revenues | $28,723 | $37,368 |
| Gross Profit | $28,723 | $21,981 |
| Net Loss | $(330,103) | $(412,921) |
| Loss Per Share | $(0.008) | $(0.010) |
| Cash and Equivalents (End of Period) | $39,307 | $7,238 |
| Total Assets | $9,544,589 | $9,719,742 |
| Total Liabilities | $1,917,716 | $1,581,974 |
| Stockholders' Equity | $7,626,873 | $8,128,768 |
Liquidity and Debt: The Company holds minimal cash ($39,307) but has significant accrued liabilities, including $401,930 in accrued interest to related parties. Total notes payable to related parties amount to $489,685. The Company reported a net cash increase of $33,967 for the quarter, driven primarily by financing activities (stock issuance proceeds of $158,971) which offset operating cash outflows of $177,504.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 23% year-over-year, dropping from $37,368 to $28,723. This was driven by a decrease in hyperthermia sales and a $60,000 return/allowance recorded in the current quarter.
- Improved Loss Position: Despite lower revenue, the Net Loss improved by roughly 20% (from $(412,921) to $(330,103)), primarily due to a significant reduction in Selling, General, and Administrative (SG&A) expenses, which fell from $413,797 to $280,009.
- Equity Fluctuation: Stockholders' equity decreased by approximately $502,000 due to the net loss for the quarter, partially offset by the issuance of 417,943 shares of common stock.
- Investment Portfolio: The Company holds an $8,000,000 investment in Aestar Fine Chemical Company and a $432,991 equity interest in Ardex Equipment L.L.C. Management announced plans to rescind the Aestar investment to repurchase shares.
Guidance, Outlook, and Risks
- Strategic Pivot: Management announced the termination of its relationship with investor Mr. Gao Yu Wen and the rescission of its 9.6% interest in Aestar Fine Chemical. The Company plans to repurchase 20 million shares of its own stock (approx. 51% of outstanding shares) to refocus on its core medical business.
- Technology Development: The Company entered an exclusive license agreement with MIT for "Adaptive Phased Array" (APA) technology to improve hyperthermia cancer treatment systems. A working prototype for breast cancer treatment has been completed with encouraging preclinical results.
- Funding: The Company has partially completed a senior secured convertible loan offering of $1.2 million to fund hyperthermia business development.
- Risks and Contingencies:
- Liquidity Risk: Cash on hand is extremely low ($39,307) relative to operating expenses and accrued liabilities.
- Regulatory Risk: Commercialization of new BPH systems and the MIT-APA technology requires FDA approval (IDE and PMA), which is time-consuming and expensive.
- Market Risk: The hyperthermia market has seen a substantial decline in recent years, and competition is increasing.
- Fiscal Year Change: The Board amended By-Laws to change the fiscal year-end from September 30 to December 31, effective December 31, 1995.
Investor Verification Checklist
- Verify the status of the proposed $2.2 million share repurchase transaction with Mr. Gao Yu Wen and the rescission of the Aestar investment.
- Confirm the timeline and funding status for the $1.2 million senior secured convertible loan offering.
- Assess the sufficiency of current cash reserves ($39,307) to cover near-term operating expenses and accrued interest payments.
- Monitor progress on FDA regulatory filings (IDE/PMA) for the BPH systems and the new MIT-APA technology.
- Review the impact of the $60,000 return/allowance on future revenue recognition and customer relationships.